Skip to content

Study · Animal study (in vivo) · rat · 1993

10 results

Effects of interactions between IGFBPs and IGFs on the plasma clearance and in vivo biological activities of IGFs and IGF analogs.

Ballard FJ, Walton PE, Bastian S, Tomas FM, Wallace JC, Francis GL

Growth regulation1 Mar 1993Cited by 14 (Europe PMC)

PMID7683526 (opens in a new tab)PepBankPUB-07683526
Publisher pageAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In normal female rats, chronic administration of IGF-I and LR3IGF-I over 14 days produced marked increases in body weight.

    In plain wordsIn rats, 14 days of treatment with IGF-I or the LR3 IGF-I analogue increased body weight markedly.

    Peptide
    IGF-1 LR3
    Outcome
    IncreaseBody weight
    Study

    ratn: not reported in source

    normal female rats
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 14 daysAs given in this study (rat).

    Source sentences

    Summary
    Chronic administration of the peptides over 14 days to normal female rats produces marked increases in body weight, nitrogen retention and food conversion efficiency as well as retention of the carcass composition and fractional weights of the gut, spleen and thymus that are characteristic of the younger age.
    1 context sentence
    Summary · context
    The relative activities in vivo of IGFs that differ in their association affinities towards IGF binding proteins (IGFBPs) have been examined in a series of comparisons between IGF-I and LR3IGF-I.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In normal female rats, chronic administration of IGF-I and LR3IGF-I over 14 days produced marked increases in nitrogen retention.

    In plain wordsIn rats, 14 days of treatment with IGF-I or the LR3 IGF-I analogue increased nitrogen retention markedly.

    Peptide
    IGF-1 LR3
    Outcome
    IncreaseNitrogen retention
    Study

    ratn: not reported in source

    normal female rats
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 14 daysAs given in this study (rat).

    Source sentences

    Summary
    Chronic administration of the peptides over 14 days to normal female rats produces marked increases in body weight, nitrogen retention and food conversion efficiency as well as retention of the carcass composition and fractional weights of the gut, spleen and thymus that are characteristic of the younger age.
    1 context sentence
    Summary · context
    The relative activities in vivo of IGFs that differ in their association affinities towards IGF binding proteins (IGFBPs) have been examined in a series of comparisons between IGF-I and LR3IGF-I.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In normal female rats, chronic administration of IGF-I and LR3IGF-I over 14 days produced marked increases in food conversion efficiency.

    In plain wordsIn rats, 14 days of treatment with IGF-I or the LR3 IGF-I analogue improved how well food turned into weight.

    Peptide
    IGF-1 LR3
    Outcome
    IncreaseFood conversion efficiency
    Study

    ratn: not reported in source

    normal female rats
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 14 daysAs given in this study (rat).

    Source sentences

    Summary
    Chronic administration of the peptides over 14 days to normal female rats produces marked increases in body weight, nitrogen retention and food conversion efficiency as well as retention of the carcass composition and fractional weights of the gut, spleen and thymus that are characteristic of the younger age.
    1 context sentence
    Summary · context
    The relative activities in vivo of IGFs that differ in their association affinities towards IGF binding proteins (IGFBPs) have been examined in a series of comparisons between IGF-I and LR3IGF-I.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In normal female rats, chronic administration of the peptides over 14 days retained the carcass composition characteristic of the younger age.

    In plain wordsIn rats, 14 days of treatment with IGF-I or the LR3 IGF-I analogue kept carcass composition like that of younger animals.

    Peptide
    IGF-1 LR3
    Outcome
    Not applicableCarcass composition
    Study

    ratn: not reported in source

    normal female rats
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 14 daysAs given in this study (rat).

    Source sentences

    Summary
    Chronic administration of the peptides over 14 days to normal female rats produces marked increases in body weight, nitrogen retention and food conversion efficiency as well as retention of the carcass composition and fractional weights of the gut, spleen and thymus that are characteristic of the younger age.
    1 context sentence
    Summary · context
    The relative activities in vivo of IGFs that differ in their association affinities towards IGF binding proteins (IGFBPs) have been examined in a series of comparisons between IGF-I and LR3IGF-I.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In normal female rats, chronic administration of the peptides over 14 days retained the fractional weights of the gut, spleen and thymus characteristic of the younger age.

    In plain wordsIn rats, 14 days of treatment with IGF-I or the LR3 IGF-I analogue kept gut, spleen and thymus weights like those of younger animals.

    Peptide
    IGF-1 LR3
    Outcome
    Not applicableFractional weights of gut, spleen and thymus
    Study

    ratn: not reported in source

    normal female rats
    Outcome group
    Body weight · Whole body
    Studied dose
    Dose not stated · 14 daysAs given in this study (rat).

    Source sentences

    Summary
    Chronic administration of the peptides over 14 days to normal female rats produces marked increases in body weight, nitrogen retention and food conversion efficiency as well as retention of the carcass composition and fractional weights of the gut, spleen and thymus that are characteristic of the younger age.
    1 context sentence
    Summary · context
    The relative activities in vivo of IGFs that differ in their association affinities towards IGF binding proteins (IGFBPs) have been examined in a series of comparisons between IGF-I and LR3IGF-I.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In growth measurements in rats, LR3IGF-I was 6 fold more potent than IGF-I.

    In plain wordsIn rats, the LR3 IGF-I analogue was 6 times more potent than IGF-I for growth.

    Peptide
    IGF-1 LR3
    Outcome
    IncreaseGrowth potency versus IGF-I
    Study

    ratn: not reported in source

    normal female rats
    Comparator
    IGF-I
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    growth potency ratio LR3IGF-I to IGF-I
    6 fold
    rat growth measurements

    Source sentences

    Summary
    In the growth measurements LR3IGF-I is 6 fold more potent than IGF-I, thus reflecting the in vitro difference.
    1 context sentence
    Summary · context
    The relative activities in vivo of IGFs that differ in their association affinities towards IGF binding proteins (IGFBPs) have been examined in a series of comparisons between IGF-I and LR3IGF-I.
  7. 07AnimalAnimal study (in vivo)Pharmacokinetics

    In rats, LR3IGF-I was removed from the plasma much more rapidly than IGF-I.

    In plain wordsIn rats, the LR3 IGF-I analogue cleared from the blood much faster than IGF-I.

    Peptide
    IGF-1 LR3
    Outcome
    IncreasePlasma clearance versus IGF-I
    Study

    ratn: not reported in source

    normal female rats
    Comparator
    IGF-I
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In a second series of experiments in which the clearance rates of the two peptides were compared, LR3IGF-I was shown to be removed from the plasma much more rapidly than was IGF-I, a difference reflecting the poor association of LR3IGF-I with plasma IGFBPs.
    1 context sentence
    Summary · context
    The relative activities in vivo of IGFs that differ in their association affinities towards IGF binding proteins (IGFBPs) have been examined in a series of comparisons between IGF-I and LR3IGF-I.
  8. 08AnimalAnimal study (in vivo)Pharmacokinetics

    In pregnant rats, where IGFBP levels are markedly reduced, only the clearance of IGF-I was affected, and LR3IGF-I clearance was not.

    In plain wordsIn pregnant rats, the clearance of the LR3 IGF-I analogue did not change, while IGF-I cleared nearly as fast as the analogue.

    Peptide
    IGF-1 LR3
    Outcome
    No significant changePlasma clearance in pregnant rats
    Study

    ratn: not reported in source

    pregnant rats with reduced IGFBP levels
    Comparator
    IGF-I
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In this condition only the clearance of IGF-I was affected to produce a clearance rate almost as rapid as that found with LR3IGF-I.
    2 context sentences
    Summary · context
    The crucial relevance of binding protein association in explaining the difference was confirmed in pregnant rats where IGFBP levels are markedly reduced.
    Summary · context
    The relative activities in vivo of IGFs that differ in their association affinities towards IGF binding proteins (IGFBPs) have been examined in a series of comparisons between IGF-I and LR3IGF-I.
  9. 09LabIn vitro (cells)Activity measurement

    In cultured L6 myoblasts, the reduced association with IGFBPs gave LR3IGF-I a 5-10 fold greater biological potency than IGF-I.

    In plain wordsIn cells, the LR3 IGF-I analogue was 5 to 10 times more potent than IGF-I.

    Peptide
    IGF-1 LR3
    Outcome
    IncreaseBiological potency in L6 myoblasts
    Study

    ratn: not reported in source

    cultured L6 myoblasts
    Comparator
    IGF-I
    Outcome group
    Receptor activity and mechanism · Musculoskeletal
    Studied dose
    Dose not stated

    Measurements

    potency ratio LR3IGF-I to IGF-I
    5 to 10 fold
    L6 myoblasts

    Source sentences

    Summary
    In cultured L6 myoblasts the reduced association with IGFBPs gives LR3IGF-I a 5-10 fold greater biological potency.
    1 context sentence
    Summary · context
    The relative activities in vivo of IGFs that differ in their association affinities towards IGF binding proteins (IGFBPs) have been examined in a series of comparisons between IGF-I and LR3IGF-I.
  10. 10LabIn vitro (cell-free)Activity measurement

    IGF-I had approximately 1000 fold higher affinity than LR3IGF-I towards IGFBP-3, IGFBP-4, total rat plasma IGFBPs and L6 myoblast binding protein.

    In plain wordsIn lab tests, the LR3 IGF-I analogue bound IGF-binding proteins about 1000 times less strongly than IGF-I did.

    Peptide
    IGF-1 LR3
    Outcome
    DecreaseBinding affinity for IGFBPs versus IGF-I
    Study

    n: not reported in source

    IGFBP-3, IGFBP-4, rat plasma IGFBPs and L6 myoblast binding protein
    Comparator
    IGF-I
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Measurements

    affinity ratio IGF-I to LR3IGF-I
    ≈ 1000 fold
    IGFBP-3, IGFBP-4, rat plasma IGFBPs, L6 myoblast BP

    Source sentences

    Summary
    IGF-I has approximately 1000 fold higher affinity than LR3IGF-I towards IGFBP-3, IGFBP-4, total rat plasma IGFBPs and L6 myoblast BP.
    1 context sentence
    Summary · context
    The relative activities in vivo of IGFs that differ in their association affinities towards IGF binding proteins (IGFBPs) have been examined in a series of comparisons between IGF-I and LR3IGF-I.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.